Another RLF loose connection

[jonny80s]

Once again there is a loose connection to Relief Therapeutics/NeuroRx Javitt has worked with Mannkind(it is listed at the end):

www.bloomberg.com/press-releases/2020-09-21/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners

[goyocafe]

Sept 21, 2020 5:00:14 GMT -5 jonny80s said:

Once again there is a connection to Relief Therapeutics/NeuroRx Javitt has worked with Mannkind(it is listed at the end):

www.bloomberg.com/press-releases/2020-09-21/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners

This gives a great deal of literary freedom to the word “tangential “. Always nice to know great people once walked the halls of Mannkind, but I don’t see any more than that here. Glad to see others making good progress on Covid therapies.



But wait, there’s more! 

From May, 2020
www.biospace.com/article/releases/relief-therapeutics-announces-filing-of-ind-for-phase-2-3-clinical-trial-of-inhaled-rlf-100-targeting-early-covid-19-lung-injury/

They never say what company or inhalation platform is being used for this. I got excited for a split second, but disbelief won me over. Surely we’d have heard about this already, right? Am I late to the party here and this has already been debunked as far as our little company is concerned?


August, 2020
www.contagionlive.com/news/fda-grants-ind-for-inhaled-therapy-for-patients-with-moderate-and-severe-covid19

Whoes inhalation platform?

[peppy]

Sept 21, 2020 5:00:14 GMT -5 jonny80s said:

Once again there is a connection to Relief Therapeutics/NeuroRx Javitt has worked with Mannkind(it is listed at the end):

www.bloomberg.com/press-releases/2020-09-21/relief-and-neurorx-announce-partnership-for-global-commercialization-of-rlf-100-and-selection-of-commercial-partners

Relief and NeuroRx Announce Partnership for Global Commercialization of
RLF-100™ and Selection of Commercial Partners

- RLF-100™ (Aviptadil) is in advanced stages of phase 2b/3 development in the
US

- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane
oxygenation) has been reported under FDA Emergency Use IND authorization at
multiple clinical sites

===============================================================================

Aviptadil (RLF-100) COVID-19 Therapeutic
Aviptadil is a formulation of synthetic human Vasoactive Intestinal Peptide (VIP).

VIP is known to target the VPAC1 receptor of the ATII cell and to protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. VIP prevents apoptosis, blocks cytokines, lowers TNFα levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.

Aviptadil COVID-19 Therapeutic Indication
Aviptadil COVID-19 Therapeutic is being used to treat Novel Corona Virus (SARS-CoV-2) that is known to cause Respiratory Failure, which is the hallmark of Acute COVID-19, as defined by the new NIH/FDA classification.

Approximately 50% of those who develop Critical COVID-19 die, despite intensive care and mechanical ventilation.

Patients with Critical COVID-19 and respiratory failure, currently treated with high flow nasal oxygen, non-invasive ventilation or mechanical ventilation will be treated with RLF-100 (Aviptadil).

========================================================================================
Just looking.
suffixes Aviptadil, tadalafil.